Stay updated on Ipilimumab Nivolumab Combo in Mesothelioma Clinical Trial
Sign up to get notified when there's something new on the Ipilimumab Nivolumab Combo in Mesothelioma Clinical Trial page.

Latest updates to the Ipilimumab Nivolumab Combo in Mesothelioma Clinical Trial page
- Check3 days agoChange DetectedThe page's revision history shows an addition of Revision: v3.3.4 and a deletion of Revision: v3.3.3. This reflects metadata updates rather than changes to the study data.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedA new Locations section including North Holland was added, and the HHS Vulnerability Disclosure and North Holland Locations entries were removed; the page revision updated to v3.3.3.SummaryDifference0.2%

- Check46 days agoChange DetectedPage revision updated from v3.3.1 to v3.3.2. No changes to the study details or substantive content.SummaryDifference0.1%

- Check53 days agoChange DetectedAdded a note that publications are automatically filled from PubMed and may not all be about the study, and updated the revision to v3.3.1. The previous wording stating publications come from PubMed (and the older revision v3.2.0) was removed.SummaryDifference0.1%

- Check61 days agoChange DetectedThe notice about a lapse in government funding and possible update delays has been removed; the study page content remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check75 days agoChange DetectedComparison shows no substantive changes to the study details (eligibility, endpoints, or locations). The observed differences are minor visual/layout tweaks and do not affect the information presented.SummaryDifference0.4%

Stay in the know with updates to Ipilimumab Nivolumab Combo in Mesothelioma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipilimumab Nivolumab Combo in Mesothelioma Clinical Trial page.